PFT

PROCEDURE3 trials

Sponsors

National Heart, Lung, and Blood Institute (NHLBI), University of Pittsburgh, National Cancer Institute (NCI)

Conditions

AgingCOPDCarcinoma In SituCervical Intraepithelial NeoplasiaHIVLymphangioleiomyomatosisPapillomavirus InfectionsPulmonary Disease

Phase 1

Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis

RecruitingNCT01799538

National Heart, Lung, and Blood Institute (NHLBI)Lymphangioleiomyomatosis

Start: 2013-06-10End: 2027-11-01Target: 100Updated: 2026-03-20

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

CompletedNCT02858310

National Cancer Institute (NCI)Carcinoma In Situ, Cervical Intraepithelial Neoplasia, Papillomavirus Infections +2

Start: 2017-01-27End: 2025-07-02Updated: 2026-03-09

Unknown Phase

Translation Evaluation of Aging, Inflammation and HIV in Lung Function (TEAL)

CompletedNCT02154880

University of PittsburghAging, COPD, HIV +1

Start: 2014-02-28End: 2020-03-02Updated: 2020-10-08

Related Papers

TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers.

2021-02-08258 citations

Safety and clinical activity of gene-engineered T-cell therapy targeting HPV-16 E7 for epithelial cancers.

Journal of Clinical Oncology2020-05-2020 citations

Engineered t cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.

Journal of Clinical Oncology2018-05-205 citations

Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model

JCI Insight2018-04-18159 citations